Chemoprevention of skin melanoma: Facts and myths

Melanoma Research

Volumn 23, Issue 6, 2013, Pages 426-433

  Uzarska, Małgorzata ^a   Czajkowski, Rafał ^b   Schwartz, Robert A ^d   Bajek, Anna ^a   Zegarska, Barbara ^c   Drewa, Tomasz ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Department of Dermatology   (Poland)

^c Department of Cosmetology and Esthetic Dermatology ^*  (Poland)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

apigenin; chemoprevention; curcumin; cyclooxygenase inhibitors; fibrates; genistein; melanoma; quercetin; resveratrol; statins

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; CALCITRIOL; CATECHIN; CELECOXIB; COLECALCIFEROL; CURCUMIN; DAIDZEIN; DICLOFENAC; FIBRIC ACID DERIVATIVE; FLAVONOID; GENISTEIN; IBUPROFEN; IMIQUIMOD; INDOMETACIN; MEVINOLIN; NAPROXEN; PARACETAMOL; PIROXICAM; PROSTAGLANDIN; RESVERATROL; RETINOID; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SILYMARIN; SULFORAPHANE; SULINDAC;

ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; ISOPRENYLATION; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; MELANOMA; MELANOMA CELL; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION;

AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; CURCUMIN; FLAVONOIDS; HUMANS; MELANOMA; PIGMENTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOIDS; RISK; SKIN; SKIN NEOPLASMS; STILBENES; TEA; TREATMENT OUTCOME; VITAMIN D;

EID: 84887626464     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000016     Document Type: Review

References (83)

1. Spagnolo F, Queirolo P. Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 2012; 304:177-184
2. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150:179-185
3. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 2010; 10:1811-1823
4. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9
5. Kycler W, Teresiak M. Skin melanoma: present possibilities of treatment in Poland based on own experiences of melanoma patients' course and current review of literature. Wspo?cz Onkol 2006; 10:437-448
6. Ruka W, Krzakowski M, Placek W, Rutkowski P, Nowecki ZI, Fijuth J, et al. Cutaneous melanoma - diagnostic and therapeutic guidelines. Oncol Clin Pract 2009; 5:20-32
7. Didkowska J, Wojciechowska U, Zaton ski W. Melanoma of skin. In: Didkowska J,Wojciechowska U, Zaton skiW, editors. Prediction of cancer incidence and mortality in Poland up to the year 2025. Warszawa: Maria Sk?odowska-Curie Memorial Cancer Center; 2009. pp. 39-44
8. Dellavalle RP, Nicholas MK, Schilling LM. Melanoma chemoprevention: a role for statins or fibrates? Am J Ther 2003; 10:203-210
9. Azfar RS, Schwartz RA, Berwick M. Primary melanoma prevention in children. G Ital Dermatol Venereol 2004; 139:267-272
10. Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol 2005; 53:225-239
11. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35:1332-1338
12. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36:2699-2702
13. De Flora S, Ferguson LR. Overview of mechanisms of cancer chemopreventive agents. Mutat Res 2005; 591:8-15
14. Bonovas S, Tsantes A, Drosos T, Sitaras NM. Cancer chemoprevention: a summary of the current evidence. Anticancer Res 2008; 28:1857-1866
15. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45:1-8
16. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993; 14:1737-1746
17. Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. J Am Acad Dermatol 2006; 55:849-861
18. Wu X, Patterson S, Hawk E. Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 2011; 25:445-459
19. Osmak M. Statins and cancer: current and future prospects. Cancer Lett 2012; 324:1-12
20. Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem 2012; 12:303-315
21. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5:930-942
22. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622
23. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 131:1460-1468
24. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98:1538-1546
25. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010; 25:29-35
26. Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis 2009; 19:751-759
27. Undas A. Anti-inflammatory and antithrombotic effects of fibrates. Pol J Cardiol 2007; 9:359-363
28. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 2007; 212:1-12
29. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418
30. Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 2005; 4:CD003697
31. Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V, Roselli M. Nonsteroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res 2007; 27:3147-3162
32. Ramirez CC, Ma F, Federman DG, Kirsner RS. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 2005; 31:748-752
33. Me ric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006; 59:51-64
34. Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011; 412:671-687
35. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001; 8:655-657
36. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129:2620-2627
37. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sørensen HAT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768-4776
38. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47-55
39. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99:608-615
40. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008; 100:967-971
41. Jeter JM, Bonner JD, Johnson TM, Gruber SB. Nonsteroidal anti-inflammatory drugs and risk of melanoma. J Skin Cancer 2011; 2011:598571
42. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127-133
43. Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004; 89-90:375-379
44. Danielsson C, Fehsel K, Polly P, Carlberg C. Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ 1998; 5:946-952
45. Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999; 133:120-128
46. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D 4th, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042-1051
47. Vinceti M, Malagoli C, Fiorentini C, Longo C, Crespi CM, Albertini G, et al. Inverse association between dietary vitamin D and risk of cutaneous melanoma in a northern Italy population. Nutr Cancer 2011; 63:506-513
48. Weinstock MA, Stampfer MJ, Lew RA,Willett WC, Sober AJ. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. J Invest Dermatol 1992; 98:809-811
49. Asgari MM, Maruti SS, Kushi LH,White E. A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol 2009; 129:1675-1680
50. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271-3281
51. Liu X, Chan SY, Ho PC. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. Cancer Chemother Pharmacol 2008; 63:167-174
52. Triozzi PL, Walker MJ, Pellegrini AE, Dayton MA. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 1996; 14:293-298
53. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol 1998; 21:352-354
54. Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, et al. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am 1999; 5:41-47
55. Garcia MS, Ono Y, Martinez SR, Chen SL, Goodarzi H, Phan T, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011; 21:235-243
56. Ellis LZ, Cohen JL, HighW, Stewart L. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature. Dermatol Surg 2012; 38:937-946
57. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 2012; 132:163-169
58. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156:337-345
59. Ren W, Qiao Z,Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev 2003; 23:519-534
60. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J Nutr Biochem 2007; 18:427-442
61. Russo A, Cardile V, Lombardo L, Vanella L, Acquaviva R. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J Nutr Biochem 2006; 17:103-108
62. Farina HG, Pomies M, Alonso DF, Gomez DE. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 2006; 16:885-891
63. Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 2010; 302:71-83
64. Vaid M, Prasad R, Sun Q, Katiyar SK. Silymarin targets b-catenin signaling in blocking migration/invasion of humanmelanoma cells. PLoS One 2011; 6:e23000
65. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000; 87:595-600
66. Hou Z, Lambert JD, Chin KV, Yang CS. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 2004; 555:3-19
67. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011; 82:1807-1821
68. Nihal M, Ahmad N, Mukhtar H,Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005; 114:513-521
69. Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH, et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1b secretion. Biochem Biophys Res Commun 2011; 414:551-556
70. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16:2-14
71. Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, et al. Effect of epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992; 65:51-54
72. Ravindranath MH, Ramasamy V, Moon S, Ruiz C, Muthugounder S. Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG). Evid Based Complement Alternat Med 2009; 6:523-530
73. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24:2783-2840
74. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008; 269:243-261
75. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM, Meadows GG. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 2003; 190:157-163
76. Larrosa M, Tomas-Barberan FA, Esp?n JC. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem 2003; 51:4576-4584
77. Hsieh TC, Wang Z, Hamby CV, Wu JM. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005; 334:223-230
78. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23:363-398
79. Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 2011; 6:31
80. Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271:305-314
81. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signalregulated protein kinase pathway and the Akt pathway. Cancer 2005; 104:879-890
82. Abusnina A, Keravis T, Yougbare I, Bronner C, Lugnier C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 2011; 55:1677-1689
83. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995; 95:221-225.